Bigul

Q2FY23 Quarterly Result Announced for Glenmark Life Sciences Ltd.

Pharmaceutical firm Glenmark Life Sciences announced Q2FY23 results: GLS registered revenue from operations of Rs 5,093 million for Q2 FY23, recording a growth of 4% QoQ and de-growth 4% (ex-covid) over a higher base of Q2 FY22 Gross Margins for the quarter were at 52.9%, up 120 bps YoY driven by a better product mix and PLI scheme benefit Earnings Before Interest, Tax, Depreciation, and Amortization (EBITDA) was at Rs 1,537 million for Q2 FY23 with margins steady at 30.2% Profit After Tax (PAT) for the quarter was at Rs 1,069 million in Q2 FY23, registering a de-growth of 7.2% YoY. PAT Margin for the quarter was at 21% up by 50bps YoY Dr. Yasir Rawjee, MD & CEO, Glenmark Life Sciences Limited said, “I am pleased to share that despite global uncertainties, the Company exhibited growth on a sequential basis. External businesses (ex-GPL) was the key driver for this quarter, growing 13% YoY basis and 16% QoQ. India, LATAM, and Japan drove the growth during the quarter. The CDMO business also showed momentum, posting 27% growth QoQ. ” Dr. Rawjee further added, “I am happy to announce that we have completed the Dahej Capex and commenced commercial production from the third quarter. The new capacity will help us achieve the next leg of growth in the coming years. We remain confident of growing steadily in coming quarters with our differentiated products and wide geographical reach.” Tushar Mistry, CFO, of Glenmark Life Sciences Limited said, “The revenue for this quarter registered a 4% sequential growth despite a substantial degrowth in the GPL business. EBITDA margins at 30.2% was steady. The resilient margin profile in the face of global uncertainties has come on the back of continuous focus on cost improvement programs, efficient supply chain management and the intrinsic fact that our products are high-value niche molecules. With all the planned capex in place, the company is uniquely positioned to address the opportunities with its differentiated product offerings across a wide geography.” Result PDF
21-10-2022
Bigul

Glenmark Life Sciences Ltd - 543322 - Unaudited Financial Results For The Second Quarter And Half Year Ended September 30, 2022

Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that the Board at its meeting held today approved the Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2022. The said meeting of the Board commenced at 11.30 a.m. and concluded at 01.10 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarklifesciences.com
21-10-2022
Bigul

Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Enclosed please find herewith the revised details of Earnings Call slated for Friday, October 21, 2022 at 4:00 p.m. - 5:00 p.m. (IST), for your information and record.
17-10-2022
Bigul

Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Enclosed please find herewith the details of Earnings Call slated for Friday, October 21, 2022 at 5:00 p.m. - 6:00 p.m. (IST), for your information and record.
17-10-2022
Bigul

Glenmark Life Sciences Ltd - 543322 - Closure of Trading Window

We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, October 21, 2022, inter alia, to consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2022. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from September 30, 2022 to October 23, 2022 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the second quarter and half year ended September 30, 2022.
14-10-2022
Bigul

Glenmark Life Sciences Ltd - 543322 - Board Meeting Intimation for Unaudited Financial Results Of The Company For The Second Quarter And Half Year Ended September 30, 2022

Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/10/2022 ,inter alia, to consider and approve We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, October 21, 2022, inter alia, to consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2022. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from September 30, 2022 to October 23, 2022 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the second quarter and half year ended September 30, 2022.
14-10-2022
Bigul

Glenmark Life Sciences Ltd - 543322 - Statement Of Investor Complaints For The Quarter Ended September 2022

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1010 Name of the Signatory :- Rudalf CorrieaDesignation :- Company Secretary and Compliance Officer
12-10-2022
Bigul

Glenmark Life Sciences Ltd - 543322 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

Proceedings and Scrutinizer's Report of the 11th Annual General Meeting (AGM) of Glenmark Life Sciences Limited ('the Company') held on September 26, 2022
26-09-2022
Bigul

Glenmark Life Sciences Ltd - 543322 - Shareholder Meeting / Postal Ballot-Outcome of AGM

Proceedings and Scrutinizer's Report of the 11th Annual General Meeting (AGM) of Glenmark Life Sciences Limited ('the Company') held on September 26, 2022
26-09-2022
Bigul

Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Advertisement of Notice of 11th Annual General Meeting, E-voting Information and Book Closure
01-09-2022
Next Page
Close

Let's Open Free Demat Account